MetaCap

Kura Oncology (KURA) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sagimet Biosciences Series A (SGMT) has outperformed Kura Oncology (KURA) over the past year, gaining 36.1% versus a loss of 38.1%. Sagimet Biosciences Series A is the larger company by market cap ($648.0 million vs $634.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KURA-38.14%SGMT+36.13%
+77%+16%-45%
Nov 21, 20251 yearNov 20, 2026
KURA-31.18%SGMT-43.07%
+145%+24%-98%
Jul 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KURA versus SGMT key metrics
MetricKURASGMT
Share price$6.91$9.08
Market cap$634.88M$648.02M
1-day change-5.99%-5.61%
YTD return-33.49%+53.38%
1-year return-38.14%+36.13%
5-year return-50.66%—
EPS (TTM)$-3.30$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.48M—
Revenue growth (YoY)+25.24%—
Net income (latest FY)$-278.67M$-51.04M
Operating margin-449.94%—
Net margin-412.95%—
52-week high$13.90$11.45
52-week low$6.75$4.50
Distance from 52-week high-50.29%-20.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+357.60%+200.33%
Average volume2.10M1.23M
Shares outstanding91.88M71.37M
Employees26016
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SGMT has outperformed KURA by 74.3 percentage points over the past year.

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

KURA vs SGMT FAQ

Which is bigger, Kura Oncology or Sagimet Biosciences Series A?

Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $648.02M compared with $634.88M for Kura Oncology (KURA).

Which stock has performed better over the past year, KURA or SGMT?

SGMT returned +36.13% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.

Are Kura Oncology and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons